Five-Year Outcome in Pediatric Patients With Mycophenolate Mofetil-Based Renal Transplantation

Abstract

MMF based protocols improved long-term graft survival without an increase in side effects. Early ARE were associated with worse half-life of the graft, although more stressed in the AZA group. Thus, to improve quality of life in children for very long-term outcome, ARE should be further decreased and renal function should be better preserved.

De novoTherapy with Everolimus, Low‐Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation

“…biopsies showed no acute rejection or borderline findings (Figure 2 10-20% has also been shown in other large trials after pediatric KTX (7,8,13) (15,23) and even after allogeneic hematopoietic stem cell transplantation (24). We also saw a reduction of the numbers of i.v.…”

Pediatric Kidney Transplantation Followed by De Novo Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data

“…The absence of acute rejections in the first 3 years after KTX and treatment with basiliximab/everolimus/low-dose CsA is remarkable, as acute rejections (10%-20%) were reported after pediatric KTX in other large trials (7)(8)(9) and in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry (3). The mean GFR measured at 1-year post-KTX was not lower in this study, as in the large European basiliximab trial (2).…”

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

“…The incidence of acute rejection is markedly lower, ranging from 15 to 35%, in patients who received MMF compared with those who received either azathioprine or no antimetabolite in combination with a CNI and corticosteroids (85)(86)(87)(88)(89). MMF has also been found to improve 5-year outcome in pediatric renal transplant recipients and prolong half-life of the graft (90).…”